
ASCO-GI 2019—Pembrolizumab shows OS advantage in PD-L1 esophageal cancer
(...)
The resource you are trying to access is only available for registered users. To continue please login or create a Univadis® account.
-
Log in
-
Register to Univadis for FREE
- Find relevant information quickly
- Regular updates of specialty information
- Helpful resources at the point of care
- Educate your patients with quality health information
- Access to world-leading medical publishers
Featured Channels
Most recent
-
ASCO-GU 2019—Avelumab+axitinib bests sunitinib in previously untreated clear-cell aRCC
Tuesday 19 February 2019
-
ASCO-GU 2019—Darolutamide improves MFS in castration-resistant prostate cancer
Tuesday 19 February 2019
-
ASCO-GU 2019—Enzalutamide+ADT extends radiographic PFS in mHSPC
Tuesday 19 February 2019
-
ASCO-GU 2019—OS advantage for abiraterone+prednisone+ADT in metastatic prostate cancer
Tuesday 19 February 2019
-
ASCO-GU 2019—Pembrolizumab+axitinib better than sunitinib in advanced or metastatic clear-cell RCC
Tuesday 19 February 2019
-
ASCO-GI 2019—Durvalumab-tremelimumab extends OS in refractory CRC
Wednesday 23 January 2019
-
ASCO-GI 2019—FTD/TPI effective for mGC regardless of prior gastrectomy
Wednesday 23 January 2019
-
ASCO-GI 2019—NACT tops upfront surgery for PDAC in phase 2/3 trial
Wednesday 23 January 2019
-
ASCO-GI 2019—Pembrolizumab shows OS advantage in PD-L1 esophageal cancer
Wednesday 23 January 2019